Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0869
Source ID: NCT02145325
Associated Drug: Expanded Tregs
Title: Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients
Acronym: TRACT
Status: COMPLETED
Study Results: NO
Results:
Conditions: End Stage Renal Disease
Interventions: DRUG: Expanded Tregs
Outcome Measures: Primary: Safety Profile Assessment of TRACT, The primary safety endpoint is the evaluation of cellular related toxicities immediately and within 24 hrs post infusion of TRACT. Since TRACT is being administered to promote immunosuppression and prevent rejection, specific adverse events (subsequent rejection episodes, allosensitization, development of opportunistic infection) within 30 days of infusion will be monitored., 5 years (60 weeks) |
Sponsor/Collaborators: Sponsor: Northwestern University
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 10
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2014-04
Completion Date: 2016-06-16
Results First Posted:
Last Update Posted: 2019-10-08
Locations: Northwestern University Comprehensive Transplant Center, Chicago, Illinois, 60611, United States
URL: https://clinicaltrials.gov/show/NCT02145325